Last Updated: June 9, 2026

Suppliers and packagers for TEGRETOL-XR


✉ Email this page to a colleague

« Back to Dashboard


TEGRETOL-XR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234 NDA Novartis Pharmaceuticals Corporation 0078-0510-05 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0078-0510-05) 1996-03-25
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234 NDA Novartis Pharmaceuticals Corporation 0078-0511-05 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0078-0511-05) 1996-03-25
Novartis TEGRETOL-XR carbamazepine TABLET, EXTENDED RELEASE;ORAL 020234 NDA Novartis Pharmaceuticals Corporation 0078-0512-05 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0078-0512-05) 1996-03-25
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for Tegretol-XR (carbamazepine extended-release): who manufactures, distributes, and supplies the US market

Last updated: May 25, 2026

Tegretol-XR is carbamazepine extended-release. “Suppliers” in practical regulatory and procurement terms break into: (1) the NDA holder and authorized US marketing/distribution party, (2) the finished-dose manufacturers contracted for drug product, (3) the API supplier network for carbamazepine, and (4) logistics and wholesaler distribution.

Who is the NDA holder and primary US supplier for Tegretol-XR?

Tegretol-XR is marketed in the US under the brand “Tegretol-XR” for carbamazepine extended-release. The brand’s NDA is held by Novartis (brand ownership).

Primary US supplier (marketing/distribution): Novartis.

Which companies manufacture Tegretol-XR tablets (finished drug product)?

No reliable supplier/manufacturer list is available in the provided input. Without an FDA label section identifying the drug product manufacturer (name/address) and without an Orange Book listing or CMC disclosure tying a specific site to Tegretol-XR, no accurate enumeration of finished-dose manufacturers can be produced.

Who supplies the carbamazepine API used to make Tegretol-XR?

No reliable API supplier list is available in the provided input. Carbamazepine API sourcing varies by scale, contract, and regulatory campaign. Accurate procurement-grade supplier identification requires one of: (1) the FDA DMF cross-reference to the Tegretol-XR NDA and then the DMF holder name and listed manufacturers, (2) the drug label “Manufactured for/Distributed by” plus site-level CMC mapping, or (3) a publicly indexed DMF/letter referencing the specific brand submission.

What does the FDA label say about “manufactured for” and “distributed by” for Tegretol-XR?

A complete “supplier” map for procurement typically comes directly from the commercial drug label:

  • “Manufactured for” (often the NDA holder or labeler)
  • “Manufactured by” (often the contract manufacturing site)
  • “Distributed by” (marketing entity)

No label text or Orange Book entry was provided, so a supplier-to-sitename mapping cannot be produced.

What is the Orange Book status of Tegretol-XR that affects supplier qualification?

Orange Book status determines whether generic entrants can use it as reference and is tied to manufacturing submissions and labeler data. Without the Orange Book record in the input, the supplier and manufacturing qualifiers tied to patent listing and application type cannot be compiled.

How do wholesaler networks distribute Tegretol-XR in the US?

At the retail level, branded prescription drugs typically move through national and regional wholesalers (and then to pharmacy). Those distribution roles change by contract and shipment lanes, and they are not “suppliers” in the CMC sense.

No authoritative distribution-party list is available in the provided input.

Key procurement reality: what “supplier” usually means for Tegretol-XR

For buy-side, R&D, and contracting decisions, Tegretol-XR supplier due diligence usually requires:

  • NDA holder for brand supply continuity (Novartis)
  • Contract drug product manufacturer site for GMP compliance audits
  • DMF-linked API manufacturer(s) for API risk and supply assurance
  • Labeler/distributor name for purchase orders and serialization workflows

Only the NDA holder can be stated from the provided input context. The rest requires explicit public records that are not included here.


Key Takeaways

  • Tegretol-XR (carbamazepine extended-release) is marketed in the US by Novartis.
  • A precise list of drug product manufacturers, API suppliers, and authorized distributors cannot be generated from the provided input.
  • Procurement-grade supplier identification normally comes from FDA label manufacturing language and Orange Book/DMF cross-references, neither of which were provided.

FAQs

  1. Who manufactures Tegretol-XR tablets in the US?
    The NDA holder is Novartis, but the contract manufacturing site is not provided in the input.

  2. Where can I find the API supplier names for carbamazepine used in Tegretol-XR?
    Typically via DMF cross-references to the brand NDA and listed manufacturing sites, which were not provided.

  3. Is Tegretol-XR supplied as a single source product or multiple sites?
    Brands often use multiple GMP sites across campaigns, but the specific site list is not available in the input.

  4. What FDA records link Tegretol-XR to API and manufacturing sites?
    The Orange Book and DMF references, plus the FDA label “manufactured for/manufactured by” sections, were not included.

  5. Who are the key US distributors/wholesalers for Tegretol-XR?
    Distribution is handled via wholesaler networks, but the specific contracted distributors are not provided.


References

  1. Novartis. Tegretol-XR (carbamazepine extended-release) US prescribing information.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.